Cargando…

Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer

Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5 mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2–3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free...

Descripción completa

Detalles Bibliográficos
Autores principales: Helle, S I, Geisler, J, Anker, G B, Leirvaag, B, Holly, J M P, Lønning, P E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364048/
https://www.ncbi.nlm.nih.gov/pubmed/11461068
http://dx.doi.org/10.1054/bjoc.2001.1871
_version_ 1782153856827785216
author Helle, S I
Geisler, J
Anker, G B
Leirvaag, B
Holly, J M P
Lønning, P E
author_facet Helle, S I
Geisler, J
Anker, G B
Leirvaag, B
Holly, J M P
Lønning, P E
author_sort Helle, S I
collection PubMed
description Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5 mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2–3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2 and IGFBP-3 were measured by radioimmuno-/immunoradiometric-assays. All samples were subjected to Western ligand blotting as well as immunoblotting for IGFBP-3. We observed a significant decrease (percentage of pretreatment levels with 95 confidence intervals of the mean) in IGF-I [2 weeks 63% (49–79); 1 month 56% (44–73); 2–3 months 66% (53–82)], IGF-II [2 weeks 67% (56–80); 1 month 60% (52–68); 2–3 months 64% (55–75)], free IGF-I [2 weeks 29% (19–42); 1 month 25% (18–36); 2–3 months 31% (21–46)], IGFBP-2 [2 weeks 53% (18–156); 1 month 69% (61–78); 2–3 months 66% (57–78)], IGFBP-3 [2 weeks 74% (63–85); 1 month 69% (62–76); 2–3 months 71% (63–80)], as well as IGFBP-3 protease activity [2 weeks 71% (54–95); 1 month 78% (64–94); 2–3 months 71% (54–93)]. Contrary, the plasma levels (percentage of pretreatment levels with 95 confidence intervals of the mean) of IGFBP-1 [2 weeks 250% (127–495); 1 month 173% (138–542); 2–3 months 273% (146–510)] and IGFBP-4 [2 weeks 146% (112–192); 1 month 140% (116–169); 2–3 months 150% (114–198)] increased significantly. While this study confirms previous observations during treatment with oral oestrogens in substitution doses, the reduction in plasma IGF-II, free IGF-I, IGFBP-2 and -3 are all novel findings. A profound decrease in free IGF-I suggests a reduced bioavailability of IGFs from plasma to the tissues. These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses. © 2001 Cancer Research Campaign http://www.bjcancer.com
format Text
id pubmed-2364048
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23640482009-09-10 Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer Helle, S I Geisler, J Anker, G B Leirvaag, B Holly, J M P Lønning, P E Br J Cancer Regular Article Alterations in the insulin-like growth factor (IGF)-system were evaluated in 16 patients treated with diethylstilboestrol 5 mg 3 times daily. Fasting blood samples were obtained before treatment and after 2 weeks, 1 month and/or 2–3 months on therapy. Insulin-like growth factor (IGF)-I, IGF-II, free IGF-I, IGF-binding protein (IGFBP)-1, IGFBP-2 and IGFBP-3 were measured by radioimmuno-/immunoradiometric-assays. All samples were subjected to Western ligand blotting as well as immunoblotting for IGFBP-3. We observed a significant decrease (percentage of pretreatment levels with 95 confidence intervals of the mean) in IGF-I [2 weeks 63% (49–79); 1 month 56% (44–73); 2–3 months 66% (53–82)], IGF-II [2 weeks 67% (56–80); 1 month 60% (52–68); 2–3 months 64% (55–75)], free IGF-I [2 weeks 29% (19–42); 1 month 25% (18–36); 2–3 months 31% (21–46)], IGFBP-2 [2 weeks 53% (18–156); 1 month 69% (61–78); 2–3 months 66% (57–78)], IGFBP-3 [2 weeks 74% (63–85); 1 month 69% (62–76); 2–3 months 71% (63–80)], as well as IGFBP-3 protease activity [2 weeks 71% (54–95); 1 month 78% (64–94); 2–3 months 71% (54–93)]. Contrary, the plasma levels (percentage of pretreatment levels with 95 confidence intervals of the mean) of IGFBP-1 [2 weeks 250% (127–495); 1 month 173% (138–542); 2–3 months 273% (146–510)] and IGFBP-4 [2 weeks 146% (112–192); 1 month 140% (116–169); 2–3 months 150% (114–198)] increased significantly. While this study confirms previous observations during treatment with oral oestrogens in substitution doses, the reduction in plasma IGF-II, free IGF-I, IGFBP-2 and -3 are all novel findings. A profound decrease in free IGF-I suggests a reduced bioavailability of IGFs from plasma to the tissues. These observations may be of significance to understand the mechanisms of the antitumour effect of diethylstilboestrol in pharmacological doses. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-07 /pmc/articles/PMC2364048/ /pubmed/11461068 http://dx.doi.org/10.1054/bjoc.2001.1871 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Helle, S I
Geisler, J
Anker, G B
Leirvaag, B
Holly, J M P
Lønning, P E
Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title_full Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title_fullStr Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title_full_unstemmed Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title_short Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
title_sort alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364048/
https://www.ncbi.nlm.nih.gov/pubmed/11461068
http://dx.doi.org/10.1054/bjoc.2001.1871
work_keys_str_mv AT hellesi alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer
AT geislerj alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer
AT ankergb alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer
AT leirvaagb alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer
AT hollyjmp alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer
AT lønningpe alterationsintheinsulinlikegrowthfactorsystemduringtreatmentwithdiethylstilboestrolinpatientswithmetastaticbreastcancer